What Incyte's FY2025 10-K says: 12 signals
Incyte filed its latest 10-K with the SEC on Feb 10, 2026. It discusses data investment, acquisition completed and automation investment.
Public (INCY)Pharmaceutical Manufacturing5,001 to 10,000 employeesincyte.comLinkedIn
- Filed
- Feb 10, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 9
What Incyte's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 12 signals
This acquisition consolidates a key asset, moving from a partnership to full ownership.
MorphoSys AG
Anticipating regulatory decision and commercial launch of JAKAFI XR in mid-2026.
Following a previous FDA rejection, the company has successfully completed a new study and resubmitted its application.
Partnered with Enable Injections in Oct 2025 for enFuse on-body drug delivery system.
Incyte licensed Enable's enFuse technology for its pipeline asset INCA033989, indicating investment in novel drug delivery automation.
Enable Injections, Inc.
Secured approvals for MINJUVI in Europe and Japan for new indication in Dec 2025
The company is expanding the addressable market for its tafasitamab franchise with new approvals for follicular lymphoma in the EU and Japan, requiring investment in international commercial operations and market access strategies.
Planning to initiate two Phase 3 trials for INCA033989 in mid-to-late 2026.
The company is advancing a key pipeline asset into expensive, data-intensive Phase 3 trials for two different indications (ET and MF).
Filing for new drug indication for tafasitamab in H1 2026 after positive Phase 3 trial.
Following positive results from the frontMIND trial, Incyte will file for a major label expansion.
Incyte addresses FDA Complete Response Letter for JAKAFI XR, targeting mid-2026 launch
The company received a regulatory rejection (CRL) for its extended-release JAKAFI formulation in March 2023, causing significant delays and requiring additional studies to satisfy the FDA.
Incyte signs exclusive license with Enable Injections for new enFuse drug delivery system
Incyte is now dependent on Enable Injections' 'enFuse' on-body delivery technology for its key pipeline asset, INCA033989.
enFuse on-body delivery systemEnable Injections, Inc.
The specific mention of AI as a new risk vector indicates the company is actively using or exploring the technology.
artificial intelligence
Showing 9 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Incyte with the Signal API
One POST /v1/companies/enrich call with incyte.com returns Incyte 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"incyte.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Incyte 10-K
When did Incyte file its latest 10-K?
What does Incyte's latest 10-K say about restructuring?
Where can I find Incyte's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .